Proactive Investors - Run By Investors For Investors

4D restarts Thetanix phase I trials

The firm has been given permission to restart clinical trials on its Crohn’s Disease treatment, Thtetanix, after a four-month delay
test tubes in a laboratory
4D can now restart its Thetanix phase I trials after approval from the MHRA

Pharmaceutical company 4D Pharma PLC (LON:DDDD) has restarted phase I clinical trials of its paediatric Crohn’s Disease treatment Thetanix.

The trial was supposed to begin dosing on 1 March but had been delayed as a precaution due to quality concerns that came to light at one of the company’s suppliers during the manufacture of a batch of Thetanix.

The biotherapeutics firm has now received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the clinical study to be restarted.

4D has also completed its own investigation into the matter but gave no further details.

Thetanix is 4D’s proprietary programme for the treatment of Crohn’s Disease, a chronic bowel disease that causes inflammation and swelling across the lining of the digestive tract.

Shares were down 7.5p, or 0.9%, to 850p.

View full DDDD profile View Profile

4D Pharma Timeline

June 10 2016

Related Articles

February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use